ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy boosts radiation in endometrial cancer trial
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard radiation therapy can better prevent endometrial cancer from coming back. It includes 164 people with newly diagnosed, early-stage cancer that has a specific genetic feature (dMMR). The goal is to s…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without the disease getting worse. About 800 participants with stage III, IV, or recur…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
Virtual program aimed to ease cancer fear, but trial was withdrawn
Knowledge-focused TerminatedThis trial was designed to test whether an online mental health program could help women with advanced gynecologic or breast cancer manage their fear of the cancer coming back or getting worse. The study planned to compare the virtual program to standard educational materials. Ho…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 23, 2026 12:09 UTC